Biochem/physiol Actions

CDN1163 treatment declined the hepatic expression of genes implicated in gluconeogenesis and lipogenesis as well as attenuated endoplasmic reticulum (ER) stress response and ER stress-induced apoptosis. CDN1163 interacts with sarco/endoplasmic reticulum Ca²⁺-ATPase (SERCA) and enhances ER Ca²⁺ content.

CDN1163 is an allosteric activator of sarco/ endoplasmic reticulum Ca2+-ATPase (SERCA) that potently lowered fasting blood glucose, improved glucose tolerance and ameliorated hepatosteatosis in ob/ob mice. Additionally CDN1163 induces significant reduction in adipose tissue weight with no change in lean mass in ob/ob mice. CDN1163 has no effect on glucose levels or body weight in lean control mice.

Packaging

5, 25 mg in glass bottle